Bristol-Myers Squibb (NYSE:BMY) Shares Acquired by Wilmington Savings Fund Society FSB

Wilmington Savings Fund Society FSB boosted its stake in Bristol-Myers Squibb (NYSE:BMY) by 85.0% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 159,681 shares of the biopharmaceutical company’s stock after acquiring an additional 73,383 shares during the quarter. Wilmington Savings Fund Society FSB’s holdings in Bristol-Myers Squibb were worth $8,262,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in BMY. Lantz Financial LLC lifted its holdings in shares of Bristol-Myers Squibb by 17.4% in the second quarter. Lantz Financial LLC now owns 11,799 shares of the biopharmaceutical company’s stock valued at $490,000 after buying an additional 1,747 shares during the period. Fiduciary Financial Group LLC bought a new stake in Bristol-Myers Squibb in the second quarter worth about $201,000. Triad Wealth Partners LLC bought a new position in shares of Bristol-Myers Squibb during the 2nd quarter valued at about $79,000. Blue Trust Inc. grew its stake in shares of Bristol-Myers Squibb by 23.7% in the 2nd quarter. Blue Trust Inc. now owns 17,003 shares of the biopharmaceutical company’s stock worth $706,000 after purchasing an additional 3,263 shares during the last quarter. Finally, Stanley Laman Group Ltd. raised its holdings in shares of Bristol-Myers Squibb by 42.1% in the 2nd quarter. Stanley Laman Group Ltd. now owns 9,010 shares of the biopharmaceutical company’s stock worth $374,000 after purchasing an additional 2,670 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on BMY shares. Morgan Stanley raised their target price on shares of Bristol-Myers Squibb from $36.00 to $39.00 and gave the stock an “underweight” rating in a report on Tuesday, November 12th. Sanford C. Bernstein began coverage on Bristol-Myers Squibb in a research note on Thursday, October 17th. They set a “market perform” rating and a $56.00 price objective for the company. Leerink Partners raised Bristol-Myers Squibb from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $55.00 to $73.00 in a research report on Tuesday, November 12th. BMO Capital Markets increased their price target on Bristol-Myers Squibb from $57.00 to $61.00 and gave the company a “market perform” rating in a research report on Tuesday, November 12th. Finally, Barclays boosted their price objective on Bristol-Myers Squibb from $42.00 to $43.00 and gave the stock an “underweight” rating in a report on Monday, October 7th. Two equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, two have given a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $54.29.

Insider Transactions at Bristol-Myers Squibb

In other news, SVP Phil M. Holzer sold 700 shares of Bristol-Myers Squibb stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $55.62, for a total value of $38,934.00. Following the transaction, the senior vice president now owns 11,760 shares of the company’s stock, valued at $654,091.20. This trade represents a 5.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Samit Hirawat acquired 1,830 shares of the firm’s stock in a transaction that occurred on Friday, November 1st. The shares were purchased at an average cost of $54.67 per share, with a total value of $100,046.10. Following the completion of the acquisition, the executive vice president now owns 62,109 shares in the company, valued at $3,395,499.03. This trade represents a 3.04 % increase in their position. The disclosure for this purchase can be found here. 0.09% of the stock is currently owned by company insiders.

Bristol-Myers Squibb Trading Down 0.7 %

Bristol-Myers Squibb stock opened at $56.28 on Friday. The company has a quick ratio of 1.09, a current ratio of 1.24 and a debt-to-equity ratio of 2.83. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $61.08. The company’s fifty day simple moving average is $55.82 and its 200-day simple moving average is $49.17. The stock has a market cap of $114.15 billion, a P/E ratio of -15.68, a P/E/G ratio of 15.93 and a beta of 0.45.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.49 by $0.31. The company had revenue of $11.89 billion for the quarter, compared to analyst estimates of $11.26 billion. Bristol-Myers Squibb had a positive return on equity of 11.94% and a negative net margin of 15.30%. The business’s revenue was up 8.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.00 EPS. As a group, sell-side analysts forecast that Bristol-Myers Squibb will post 0.93 EPS for the current fiscal year.

Bristol-Myers Squibb Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, February 3rd. Shareholders of record on Friday, January 3rd will be paid a $0.62 dividend. The ex-dividend date is Friday, January 3rd. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. This represents a $2.48 dividend on an annualized basis and a yield of 4.41%. Bristol-Myers Squibb’s payout ratio is -66.85%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.